Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.49 |
| ▸ | RXRG | P48443 | 3/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003112 | 0.83 | MAPT (0.36) | RXRARXRBRXRGNR4A2PDE10A | |
| SCHEMBL14659014 | 0.75 | FFAR1 (0.42) | RXRARXRBRXRGNR4A2FFAR1 | |
| SCHEMBL1002928 | 0.74 | FAAH (0.58) | — | |
| SCHEMBL1003113 | 0.73 | DGAT1 (0.32) | HDAC4CYP2C9PDE10A | |
| SCHEMBL21624720 | 0.72 | FFAR1 (0.59) | FFAR1HDAC4CYP2C9 | |
| SCHEMBL21624718 | 0.72 | FFAR1 (0.59) | FFAR1HDAC4CYP2C9 | |
| SCHEMBL799467 | 0.69 | FFAR1 (0.59) | FFAR1HDAC4 | |
| SCHEMBL21501045 | 0.69 | FFAR1 (0.59) | FFAR1HDAC4 | |
| SCHEMBL455246 | 0.69 | FFAR1 (0.59) | FFAR1HDAC4 | |
| SCHEMBL437376 | 0.69 | FFAR1 (0.59) | FFAR1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045467-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2321288-B1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8673941-B2 | Oxazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| EP-2528603-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS | Merck Sharp & Dohme Corp. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2010017079-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171437-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | RXRA 2457/4885RXRB 2580/4885RXRG 2797/4885 |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | RXRA 2933/4885RXRB 3034/4885RXRG 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.